<i>Echinococcus multilocularis</i>infection in mice:<i>in vivo</i>treatment with a low dose of IFN-γ decreases metacestode growth and liver fibrogenesis

Liance, M.; Ricard‐Blum, Sylvie; Emery, Isabelle; Houin, R.; Vuitton, Dominique A.

doi:10.1051/parasite/1998053231

Cited by 52 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…E. multilocularis appears to induce skewed Th2-responses (Emery et al 1996). Based on in vitro and in vivo studies, Th2 dominated immunity was associated with increased susceptibility to disease, while Th1 cell activation through IL-12 (Emery et al 1996), IFNc (Jenne et al 1998 ;Liance et al 1998), TNFa (Amiot et al 1999 and IFNa (Godot et al 2003) was suggested to induce protective immunity in AE Vuitton, 2003). The intense periparasitic granulomatous infiltration indicates an intense host-parasite interaction, and the involvement of cellular immunity in control of the metacestode growth kinetics is strongly suggested by experiments carried out in T cell-deficient mouse strains (Dai et al 2004).…”

Section: H O S T R E S P O N S E T O M E T a B O L I T E S A N D S O mentioning

confidence: 99%

Triggering and modulation of the host-parasite interplay byEchinococcus multilocularis: a review

2009

View full text Add to dashboard Cite

S U M M A R YAs more facts emerge regarding the ways in which E. multilocularis-derived molecules trigger the host immune response and modulate the host-parasite interplay, it becomes possible to envisage how the parasite can survive and proliferate in its intermediate host, while in other hosts it dies out. Through effects on cells of both the innate and adaptive arms of the immune response, E. multilocularis can orchestrate a range of outcomes that are beneficial not only to the parasite, in terms of facilitating its intrahepatic proliferation and maturation, and thus life cycle over all, but also to its intermediate host, in limiting pathology. The present review deals with the role of metacestode surface molecules as well as excretory/secretory (E/S) metabolic products of the parasite in the modulation of the host responses such as to optimize its own survival.

show abstract

Section: H O S T R E S P O N S E T O M E T a B O L I T E S A N D S O mentioning

confidence: 99%

Triggering and modulation of the host-parasite interplay byEchinococcus multilocularis: a review

2009

View full text Add to dashboard Cite

show abstract

“…However, IL-12 treatment has not been evaluated as a therapeutic agent in human AE patients because of potential side-effects. Liance et al (1998) reported that the in vivo treatment of mice with a low dose (1 mg, twice a week for 3 weeks) of IFN-c decreased metacestode growth and liver fibrogenesis. The effect was dosedependent, as the treatment with a higher dose (5 mg, twice a week for 3 weeks) increased the number of metacestodes in the liver.…”

Section: Alveolar Echinococcosis (Ae)mentioning

confidence: 99%

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

et al. 2007

View full text Add to dashboard Cite

Echinococcus granulosus and Echinococcus multilocularis are cestode parasites, of which the metacestode (larval) stages cause the diseases cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively. Albendazole and mebendazole are presently used for chemotherapeutical treatment. However, these benzimidazoles do not appear to be parasiticidal in vivo against AE. In addition, failures in drug treatments as well as the occurrence of side-effects have been reported. New drugs are needed to cure AE and CE, which are considered to be neglected diseases. Strategies currently being implemented to identify novel chemotherapeutical treatment options include (i) conventional primary in vitro testing of broad-spectrum anti-infective drugs, either in parallel with, or followed by, animal experimentation ; (ii) studies of drugs which interfere with the proliferation of cancer cells and of Echinococcus metacestodes ; (iii) exploitation of the similarities between the parasite and mammalian signalling machineries, with a special focus on targeting specific signalling receptors ; (iv) in silico approaches, employing the current Echinococcus genomic database information to search for suitable targets for compounds with known modes of action. In the present article, we review the efforts toward obtaining better anti-parasitic compounds which have been undertaken to improve chemotherapeutical treatment of echinococcosis, and summarize the achievements in the field of host-parasite interactions which may also lead to new immuno-therapeutical options.

show abstract

“…IFN-γ is an important activator of macrophages and affects their energetic system (Liance et al 1998). The highest values of IFN-γ were observed after therapy L-MTP-PE + ABZ from weeks 8 to 18 p.i.…”

Section: Discussionmentioning

confidence: 91%

Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole

2008

View full text Add to dashboard Cite

The effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) administered separately or with anthelmintic albendazole (ABZ) on cellular immunity of mice with alveolar echinococcosis was studied. The proliferative activity of splenic T and B lymphocytes was the most stimulated after combined L-MTP-PE + ABZ therapy [from weeks 8 to 14 post-infection (p.i.)] that also induced a long-term development of protective Th1 response (the highest serum concentration of IFN-gamma from weeks 8 to 18 p.i.). On the contrary, Th2 response (cytokine IL-5) in infected mice treated with L-MTP-PE was inhibited since week 8 p.i., but a significant long-term decrease in IL-5 concentration was found after combined L-MTP-PE+ABZ therapy until the end of the experiment (until week 26 p.i.). L-MTP-PE stimulated the production of superoxide anion (O2-) by peritoneal macrophages from weeks 8 to 12 p.i., but the highest O2- production was accordingly recorded after therapy L-MTP-PE+ABZ from weeks 8 to 18 p.i. Stimulation of cellular immunity of mice with alveolar echinococcis with L-MTP-PE and an interaction with ABZ's anti-parasitic effect resulted in the greatest and long-term reduction of growth of Echinococcus multilocularis cysts in the host from week 10 p.i. until the end of the experiment.

show abstract

Echinococcus multilocularisinfection in mice:in vivotreatment with a low dose of IFN-γ decreases metacestode growth and liver fibrogenesis

Cited by 52 publications

References 12 publications

Triggering and modulation of the host-parasite interplay byEchinococcus multilocularis: a review

Triggering and modulation of the host-parasite interplay byEchinococcus multilocularis: a review

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole

Contact Info

Product

Resources

About